CN102170909B - 抗-notch2抗体和使用方法 - Google Patents

抗-notch2抗体和使用方法 Download PDF

Info

Publication number
CN102170909B
CN102170909B CN200980139202.1A CN200980139202A CN102170909B CN 102170909 B CN102170909 B CN 102170909B CN 200980139202 A CN200980139202 A CN 200980139202A CN 102170909 B CN102170909 B CN 102170909B
Authority
CN
China
Prior art keywords
antibody
amino acid
seq
hvr
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980139202.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102170909A (zh
Inventor
克里斯蒂安·W·西贝尔
吴岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41349057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102170909(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN102170909A publication Critical patent/CN102170909A/zh
Application granted granted Critical
Publication of CN102170909B publication Critical patent/CN102170909B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200980139202.1A 2008-10-01 2009-09-30 抗-notch2抗体和使用方法 Active CN102170909B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10191708P 2008-10-01 2008-10-01
US61/101,917 2008-10-01
PCT/US2009/059028 WO2010039832A1 (en) 2008-10-01 2009-09-30 Anti-notch2 antibodies and methods of use

Publications (2)

Publication Number Publication Date
CN102170909A CN102170909A (zh) 2011-08-31
CN102170909B true CN102170909B (zh) 2015-11-25

Family

ID=41349057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980139202.1A Active CN102170909B (zh) 2008-10-01 2009-09-30 抗-notch2抗体和使用方法

Country Status (18)

Country Link
US (5) US8404239B2 (OSRAM)
EP (1) EP2334331B1 (OSRAM)
JP (2) JP5710487B2 (OSRAM)
KR (1) KR101712214B1 (OSRAM)
CN (1) CN102170909B (OSRAM)
AR (1) AR073717A1 (OSRAM)
AU (1) AU2009298569A1 (OSRAM)
BR (1) BRPI0913827A2 (OSRAM)
CA (1) CA2736429A1 (OSRAM)
CL (1) CL2011000711A1 (OSRAM)
ES (1) ES2541726T3 (OSRAM)
IL (1) IL211623A0 (OSRAM)
MX (1) MX2011002928A (OSRAM)
PE (1) PE20120080A1 (OSRAM)
RU (1) RU2580029C2 (OSRAM)
TW (1) TW201018484A (OSRAM)
WO (1) WO2010039832A1 (OSRAM)
ZA (1) ZA201101651B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CA2729306C (en) 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
PE20120080A1 (es) * 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
JP6126991B2 (ja) * 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
EP2849785A4 (en) * 2012-05-16 2015-12-16 Oncomed Pharm Inc METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
MX357675B (es) 2012-08-13 2018-07-18 Genentech Inc Anticuerpos anti-jagged y métodos de uso.
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
MX2015011444A (es) * 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
CA2936565C (en) 2014-02-12 2020-08-11 Genentech, Inc. Anti-jagged1 antibodies and methods of use
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
US10716829B2 (en) * 2015-09-26 2020-07-21 National Health Research Institutes Method and composition for treatment of hair loss
GB201521447D0 (en) 2015-12-04 2016-01-20 Ucb Biopharma Sprl De novo antibody design
US10858443B2 (en) 2017-05-31 2020-12-08 Trustees Of Boston University Synthetic notch protein for modulating gene expression
IL299799A (en) * 2020-07-17 2023-03-01 Genentech Inc Anti-NOTCH2 antibodies and methods of use
CN121057747A (zh) * 2023-04-18 2025-12-02 上海洛启生物医药技术有限公司 抗Notch2纳米抗体及其应用
CN120441700A (zh) * 2023-11-21 2025-08-08 兰州大学第二医院 一种抗人notch2单链抗体、编码基因、试剂盒及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145840A2 (en) * 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
WO2008091641A2 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) * 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6436650B1 (en) * 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
DK1318830T3 (da) 2000-09-22 2013-01-28 Genentech Inc Konstitutivt aktiv form af Notch1-receptor eller et anti-Notch1-receptor til behandling af prostatacancer
US7083789B2 (en) * 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
US20050232927A1 (en) * 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
JP5489465B2 (ja) * 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
RU2461569C2 (ru) * 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
KR101568049B1 (ko) * 2006-12-18 2015-11-11 제넨테크, 인크. 항-ｎｏｔｃｈ3 길항제 항체 및 ｎｏｔｃｈ3-관련 질환의 예방 및 치료에 있어서 그의 용도
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CA2729306C (en) * 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
PE20120080A1 (es) * 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
RU2011151287A (ru) * 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
WO2007145840A2 (en) * 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008091641A2 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3;Kang Li 等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20080321;第283卷(第12期);8046-8054 *
Structural basis for autoinhibition of Notch;Wendy R Gordon 等;《NATURE STRUCTURAL & MOLECULAR BIOLOGY》;20070430;第14卷(第4期);295-300 *

Also Published As

Publication number Publication date
BRPI0913827A2 (pt) 2020-12-29
US20180057589A1 (en) 2018-03-01
RU2580029C2 (ru) 2016-04-10
KR101712214B1 (ko) 2017-03-03
PE20120080A1 (es) 2012-02-17
AU2009298569A1 (en) 2010-04-08
EP2334331B1 (en) 2015-04-29
TW201018484A (en) 2010-05-16
US20140314782A1 (en) 2014-10-23
RU2011117237A (ru) 2012-11-10
CA2736429A1 (en) 2010-04-08
CL2011000711A1 (es) 2012-07-20
MX2011002928A (es) 2011-04-11
KR20110061600A (ko) 2011-06-09
ES2541726T3 (es) 2015-07-23
ZA201101651B (en) 2012-06-27
US20150104461A1 (en) 2015-04-16
US20140037643A1 (en) 2014-02-06
CN102170909A (zh) 2011-08-31
JP2015145379A (ja) 2015-08-13
JP5710487B2 (ja) 2015-04-30
EP2334331A1 (en) 2011-06-22
AR073717A1 (es) 2010-11-24
IL211623A0 (en) 2011-05-31
US8404239B2 (en) 2013-03-26
US20170204175A9 (en) 2017-07-20
WO2010039832A1 (en) 2010-04-08
US20100080808A1 (en) 2010-04-01
JP2012504634A (ja) 2012-02-23

Similar Documents

Publication Publication Date Title
CN102170909B (zh) 抗-notch2抗体和使用方法
JP5577254B2 (ja) 抗ｖｅｇｆ抗体
US9096686B2 (en) E518A/K mutant smoothened and methods of using the same
TW201446798A (zh) 抗ｅｇｆｌ７抗體、包含其之組合物、編碼其之多核苷酸及其製造及使用方法
AU2013204108B2 (en) Anti-VEGF antibodies
AU2015200714A1 (en) Anti-VEGF antibodies
AU2015252098A1 (en) Mutant smoothened and methods of using the same
HK1167666B (en) Anti-fgfr3 antibodies and methods using same
HK1167666A1 (en) Anti-fgfr3 antibodies and methods using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant